Actinogen Medical Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATGGF research report →
Companywww.actinogen.com.au
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
- CEO
- Steven G. Gourlay
- IPO
- 2018
- Employees
- 6
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $2.87M
- P/E
- -6.41
- P/S
- 23.53
- P/B
- 13.71
- EV/EBITDA
- -6.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.16%
- Op Margin
- -365.31%
- Net Margin
- -326.26%
- ROE
- -134.14%
- ROIC
- -211.28%
Growth & Income
- Revenue
- $5.49M · -44.73%
- Net Income
- $-14,732,263 · -12.94%
- EPS
- $-0.00 · 18.33%
- Op Income
- $-14,932,044
- FCF YoY
- 55.22%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.98
- Avg Volume
- 8.89K
Get TickerSpark's AI analysis on ATGGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ATGGF Coverage
We haven't published any research on ATGGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATGGF Report →